Pharmaceuticals, Biotechnology and Life Sciences
150 million doses scheduled to be delivered in Q3 and Q4, 2021
With this new purchase, total of 310 million doses ordered by the European Commission to date for delivery in 2021
Contract includes an option to purchase an additional 150 million dose…
– Fourth-Quarter Revenue of $791.0 Million and Full-Year Revenue of $2.92 Billion –
– Fourth-Quarter GAAP Earnings per Share of $2.81 and Non-GAAP Earnings per Share of $2.39 –
– Full-Year GAAP Earnings per Share of $7.20 and Non-GAAP Earnings per S…
– Significantly Expands Charles River’s Scientific Capabilities in the High-Growth Cell and Gene Therapy Sector –
– Combines Cognate’s Comprehensive Cell and Gene Therapy CDMO Capabilities to Establish an Integrated Solution from Discovery through CG…
DENVER–(BUSINESS WIRE)–$CBD.U #CBD–HempFusion Wellness Inc. (TSX:CBD.U) (US:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that Mou…
– LINZESS® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% –
– 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS collaboration…
CAMBRIDGE, Mass. & BEIJING, China–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the U.S….
RADNOR, Pa.–(BUSINESS WIRE)–$MRNS #MarinusPharma–Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that Scott Braunstein, M…
Antigen Test Is the Latest Offering by Labcorp to Fight COVID-19 at Every Stage, from Diagnostic Testing to Clinical Trials and Vaccination Services
BURLINGTON, N.C.–(BUSINESS WIRE)–Labcorp (NYSE: LH), a leading global life sciences company, today a…
OlympiA Phase III trial of LYNPARZA in the adjuvant treatment of BRCA-mutated high-risk HER2-negative early breast cancer will be analyzed and reported early
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc., known as MSD outsid…
Phase 3 OlympiA Trial Evaluated LYNPARZA in Germline BRCA-mutated High-Risk HER2-Negative Early-Stage Breast Cancer Following Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–AstraZeneca…